These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16401651)

  • 1. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol was ineffective for manic episode of bipolar affective disorder.
    Zuardi A; Crippa J; Dursun S; Morais S; Vilela J; Sanches R; Hallak J
    J Psychopharmacol; 2010 Jan; 24(1):135-7. PubMed ID: 18801823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol for the treatment of psychosis in Parkinson's disease.
    Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
    J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
    McGuire P; Robson P; Cubala WJ; Vasile D; Morrison PD; Barron R; Taylor A; Wright S
    Am J Psychiatry; 2018 Mar; 175(3):225-231. PubMed ID: 29241357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
    Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
    Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
    Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Bitter I; Treuer T; Dyachkova Y; Martenyi F; McBride M; Ungvari GS
    Eur Neuropsychopharmacol; 2008 Mar; 18(3):170-80. PubMed ID: 17884390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].
    Leweke FM; Gerth CW; Koethe D; Nolden BM; Klosterkötter J
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):211-9. PubMed ID: 17230308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic effect of cannabidiol.
    Zuardi AW; Morais SL; Guimarães FS; Mechoulam R
    J Clin Psychiatry; 1995 Oct; 56(10):485-6. PubMed ID: 7559378
    [No Abstract]   [Full Text] [Related]  

  • 15. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS; Konarski JZ; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.